Selecta Biosciences
Clinical-stage biopharmaceutical company developing targeted immunotherapies using its ImmTOR platform to induce immune tolerance. Publicly traded on NASDAQ (SELB). Technology enables patients to receive gene therapies and other biologics without immune rejection.
Notes
Selecta Biosciences is a clinical-stage biopharmaceutical company developing targeted immunotherapies using its proprietary ImmTOR platform. The company is publicly traded on NASDAQ under the ticker symbol SELB and is headquartered in Watertown, Massachusetts.
The ImmTOR platform uses synthetic vaccine particles (SVP) containing rapamycin to induce antigen-specific immune tolerance. This technology has applications in:
- Enabling repeat dosing of gene therapies by preventing anti-drug antibody formation
- Treating autoimmune diseases
- Improving the efficacy of enzyme replacement therapies
Selecta's lead programs are focused on enabling gene therapy redosing and treating autoimmune conditions.
Team
- Carsten Brunn, Ph.D. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/carstenbrunn
- Takashi Kei Kishimoto, Ph.D. - Co-founder & Chief Scientific Officer
- Lloyd Johnston, CPA - Chief Financial Officer
Additional Research Findings
- NASDAQ: SELB (publicly traded)
- Portfolio company of Polaris Partners
- ImmTOR platform for immune tolerance
- Synthetic vaccine particle (SVP) technology
- Enables gene therapy redosing
- Watertown, Massachusetts headquarters
- Founded in 2007
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |